×
The $4 objective is not an analyst consensus. It reflects the January 2025 IPO price of Cellyan Biotechnology Co., Ltd (HKPD) , a psychological reference point rather than a published price target. There is no meaningful sell-side coverage: independent data providers list zero covering analysts and no consensus price target for the stock.
Cellyan Biotechnology (HKPD) fell roughly 16% over the last 30 days on a split-adjusted basis, extending a multi-month downtrend for the Hong Kong-based OTC pharmaceutical services provider. A 1-for-20 reverse stock split took effect October 26, 2026, intended to restore compliance with Nasdaq's $1.00 minimum bid price requirement.
Henry Schein (HSIC) is a global distributor of dental and medical supplies, while NiSource (NI) is a regulated natural gas and electric utility — two fundamentally different business models, growth drivers, and risk profiles. HSIC has shown stronger relative price momentum over the past year, while NI has lagged the broader market despite a compelling long-term data center growth story.
Aluminum Corporation of China (Chalco) reported third-quarter 2026 net profit attributable to shareholders of RMB 6.04 billion, up 59.10% year over year. Operating revenue for the quarter rose 1.74% to RMB 61.18 billion, reflecting a stable top line alongside sharply higher profitability.
McKesson (MCK) climbed roughly 15% over the last 30 days, from a closing price of $866.64 on September 25, 2026 to near $996.70 in late October. The biggest single catalyst was an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, which triggered a sharp one-day rally on October 1.
MEDS closed down -15.44% in the latest regular session, settling at $2.30 versus a prior close of $2.72. The sell-off followed Datavault AI's (DVLT) non-binding LOI to acquire a 19.9% equity stake in MEDS in exchange for an expanded technology license, a transaction viewed as dilutive to existing shareholders.
The $1.50 target is a technical milestone drawn from the stock's mid-2026 consolidation range, not an analyst consensus — there are no credible, attributable analyst price targets for AHG . The latest verified price is about $1.02, meaning the target implies a roughly 47% advance.
AHG traded up +4.90% to about $1.07 during regular market hours, following a prior-session close of $1.02. The move extends a multi-day speculative rally in this low-float, China-based healthcare ADR (+30.25% on Sept 30 and +13.33% on Oct 1).
Transformational pivot ahead: Akso Health Group is attempting to shift from a small Chinese social e-commerce platform toward a U.S.-focused cancer therapy and radiation oncology services model, alongside an early-stage brain-computer interface (BCI, a technology connecting brain signals to external devices) research program. Planned infrastructure build-out: The company has publicly described ambitions to establish vaccine research centers and up to roughly 100 radiation oncology centers along the U.S. East Coast, a scale that would represent a structural reinvention of the business.
SNYR fell roughly -61.37% during regular trading, dropping from its prior close of $0.2744 to about $0.106. The decline unwinds a +233% speculative spike on Sept. 16, when volume surged to over 1 billion shares.
Non-GAAP EPS of $2.91 surged 40% year-over-year, handily beating the consensus estimate of approximately $2.41. Revenue rose 6% to $63.7 billion , missing the consensus estimate of roughly $65.2 billion but reflecting solid demand across the pharmaceutical distribution business.
Cardinal Health (CAH) shares rose approximately 17.46% over the past 30 days, significantly outperforming broader market benchmarks. The stock reached new 52-week highs near $240 amid strong momentum and favorable analyst sentiment.
COR stock declined approximately -18% over the past 30 days, driven primarily by a post-earnings selloff after missing revenue expectations in fiscal Q2 2026. Over the past quarter, the stock is down around -28%, reflecting broader sector pressures and decelerating growth amid biosimilar conversions and slower GLP-1 demand.
McKesson reported Q4 fiscal 2026 adjusted EPS of $11.69, beating consensus estimates of $11.56 by 1.1%. Quarterly revenue reached $96.3 billion, up 6% year-over-year but below expectations of about $101 billion.
Cencora (COR) shares plunged 18.20% in early trading on May 6, 2026, following the release of fiscal Q2 2026 earnings before the market open. The company reported adjusted EPS of $4.75, slightly beating consensus estimates of $4.74-$4.80, but revenue of $78.4 billion missed expectations of around $81 billion.
Analysts expect Q4 fiscal 2026 EPS of approximately $11.56–$11.57, a 14% year-over-year increase. Consensus revenue estimate stands at $101.4 billion, reflecting 12% growth from last year.
MCK stock declined -8% over the past 30 days amid analyst price target adjustments and concerns over GLP-1 drug pricing pressures, despite solid fundamentals. Over the past quarter, the stock rose +3%, supported by strong Q3 fiscal 2026 earnings that beat estimates and raised full-year guidance.
The medical companies segment has experienced a notable increase in performance, recording a weekly gain of +3.53%. This sector encompasses companies involved in the production and supply of pharmaceuticals and essential medical products, catering to a broad spectrum of healthcare needs. Their product offerings include surgical apparel, gloves, hospital furniture, fluid management solutions, and specialized equipment for cosmetic and surgical procedures.
Discover the pulse of the Medical Distributors sector with a healthy 5.61% monthly rise, led by $CAH, $MCK, $HSIC, $OMI, and $PDCO. Unravel the dynamics behind this sector's growth and what it spells for future market trends.
The pets industry, encompassing various businesses related to the healthcare and daily needs of our furry friends, has recently been a hot topic among investors.